Year-end Sale % OFF 
Abstract
Prior studies of upper gastrointestinal bleeding (UGIB) and acute myocardial infarction (AMI) are small, and long-term effects of UGIB on AMI have not been delineated. We investigated whether UGIB in patients diagnosed with coronary artery disease (CAD) increased their risk of subsequent AMI. This was a population-based, nested case-control study using Taiwan’s National Health Insurance Research Database. After propensity-score matching for age, gender, comorbidities, CAD date, and follow-up duration, we identified 1,677 new-onset CAD patients with AMI (AMI[+]) between 2001 and 2006 as the case group and 10,062 new-onset CAD patients without (AMI[−]) as the control group. Conditional logistic regression was used to examine the association between UGIB and AMI. Compared with UGIB[−] patients, UGIB[+] patients had twice the risk for subsequent AMI (adjusted odds ratio [AOR] = 2.08; 95% confidence interval [CI], 1.72–2.50). In the subgroup analysis for gender and age, UGIB[+] women (AOR = 2.70; 95% CI, 2.03–3.57) and patients < 65 years old (AOR = 2.23; 95% CI, 1.56–3.18) had higher odds of an AMI. UGIB[+] AMI[+] patients used nonsignificantly less aspirin than did UGIB[−] AMI[+] patients (27.69% vs. 35.61%, respectively). UGIB increased the risk of subsequent AMI in CAD patients, especially in women and patients < 65. This suggests that physicians need to use earlier and more aggressive intervention to detect UGIB and prevent AMI in CAD patients.
Highlights
Upper gastrointestinal bleeding (UGIB) is a common, costly, and potentially life-threatening disease [1]
The adjusted odds ratio (OR) (AOR) for acute myocardial infarction (AMI)[+] patients with UGIB was 2.08
We found that patients with coronary artery disease (CAD) and UGIB, especially women and those < 65 years old, had twice the risk of developing an AMI than did CAD patients without UGIB
Summary
Upper gastrointestinal bleeding (UGIB) is a common, costly, and potentially life-threatening disease [1]. It must be managed promptly and appropriately to prevent adverse outcomes [1]. In the U.S, the annual rate of hospitalization for peptic ulcer disease and UGIB is estimated to be 165 per 100,000 in 1999—more than 300,000 hospitalizations per year, at a cost of $2.5 billion [3,4]. Despite advances in therapy, the mortality rate has remained unchanged at 7–10% [6]. This may be because today’s patients are older and have more comorbidities than did patients in the past [7]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
